CalciMedica, Inc.
No SEC Form 4 filings for $CALC in the last 30 days.
Jorey Chernett, a reporting person for CalciMedica, has filed an amended Schedule 13G/A, indicating that they no longer beneficially own any shares of the company's common stock as of May 19, 2026. This "exit filing" officially reports 0% ownership of the class. The amendment serves as a routine ownership update, though it does not detail the specifics of how or when the shares were disposed of.
CalciMedica (CALC) has filed an amendment to its annual report (10-K/A), detailing 2025 executive compensation, board governance, ownership stakes, and related-party transactions, as well as a $20.4 million private placement from 2024. The filing specifies executive pay, significant equity awards, and severance policies, with CEO A. Rachel Leheny receiving $895,410 in total compensation for 2025. It also updates information on major shareholders and outlines fees paid to the independent auditor.
CalciMedica (NASDAQ: CALC) has received two notices from Nasdaq for non-compliance, specifically for its market value of listed securities falling below $35 million and its common stock trading below the $1 minimum bid price for 30 consecutive business days. The company has 180 calendar days for each deficiency, until September 9, 2026, for market value and September 14, 2026, for bid price, to regain compliance through various alternatives, including a possible reverse stock split. Failure to do so could result in delisting from the Nasdaq Capital Market.
